Adversarial Injection · Tagraxofusp-erzs (Elzonris; SL-401; CAS 1891269-45-4; MW ~59.3 kDa; recombinant fusion cytotoxin [immunotoxin]; E. coli-expressed; refolded from inclusion bodies; human interleukin-3 [hIL-3; aa 1-125; 133 aa mature form; MW ~16.6 kDa; chromosome 5q31.1; 4-helix bundle cytokine; binds CD123/IL-3Rα with Kd ~1 nM; also binds βc chain (CSF2RB; common β-chain; shared with IL-5R and GM-CSFR) in high-affinity receptor complex] fused via Met-Gly-Gly-Ser-Gly pentapeptide linker to truncated diphtheria toxin [DT388; aa 1-388 of native DT (1535-aa precursor; 535-aa mature DT; toxin produced by Corynebacterium diphtheriae phage-encoded tox gene; 2 fragments: A [enzymatic; aa 1-186; ADP-ribosyltransferase; NAD-binding; NAD + EF-2 → ADP-ribosyl-EF-2 + nicotinamide] + B [receptor binding/translocation; aa 187-535; CRM107 mutation at aa 508 Arg→His eliminates native receptor binding → non-toxin-receptor (DT-R; HBEGF) binding eliminated; receptor-binding domain deletion aa 389-535 → DT388 construct retains A domain + T domain but lacks native receptor-binding R domain] → 388 aa truncated DT retains: A domain (NAD-dependent ADP-ribosyltransferase) + T domain (aa 205-388; membrane insertion; transmembrane helices TH8/TH9 hydrophobic; pH-dependent membrane pore formation) but lacks R domain → cannot bind normal DT receptor (HB-EGF) → instead uses IL-3 portion to target CD123]; FIRST CD123 (IL-3Rα)-DIRECTED THERAPY EVER FDA APPROVED; FIRST BPDCN-SPECIFIC THERAPY EVER FDA APPROVED; FIRST RECOMBINANT IMMUNOTOXIN EVER FDA APPROVED FOR HEMATOLOGIC MALIGNANCY: tagraxofusp IL-3 portion binds CD123 (IL-3Rα; IL3RA; chromosome Xp22.3; 378 aa type I single-pass transmembrane; extracellular: 2 Ig-like + 1 cytokine-binding domains; Kd for IL-3 alone ~30 nM; with βc co-receptor Kd ~1 nM) overexpressed on BPDCN blast cells (>99.9% blast cells CD123+; expression 10–100× above normal pDC precursors) → CD123+βc heterodimer receptor-mediated endocytosis → early endosome → acidification (pH ~5.5–6.0) → DT388 T domain (aa 205–388) conformational change → hydrophobic helices (TH8 [aa 328–348]; TH9 [aa 349–376]) insert into endosomal lipid bilayer → channel formation → A domain (DT388 aa 1–186) + T domain partial translocation → cytoplasm → A domain (ADP-ribosyltransferase; active site: His21 + Trp50 + Tyr65 form NAD-binding cleft) → NAD + diphthamide on eEF-2 (eukaryotic elongation factor 2; GTPase; chromosome 19p13.3; 858 aa; His715 post-translationally modified to 2-[3-carboxamido-3-(trimethylammonio)propyl]histidine = diphthamide by DPH1–DPH7 enzyme complex → uniquely susceptible to ADP-ribosylation) → ADP-ribosyl-eEF-2 (covalent; irreversible) + nicotinamide → eEF-2 inactivation → ribosomal translocation blocked → protein synthesis arrest → apoptosis (12–24 hours); BPDCN BIOLOGY: rare aggressive hematologic malignancy (~1000 US cases/year); arises from malignant transformation of plasmacytoid dendritic cell (pDC) precursors (pDCs: type I IFN-producing cells; CD303+/BDCA-2+/CD123high/CD4+/CD56+/CD45RA+/HLA-DR+; derive from common DC progenitor [CDP] → pDC progenitor [pDCP]); BPDCN immunophenotype: CD4+/CD56+/CD123high/BDCA-2 (CD303)+/BDCA-4 (CD304)+/TCF4 (E2-2)+/CD45RA+; absence of T (CD3), B (CD20/19), myeloid (CD33/34/117) lineage markers; clinical: typically presents with violaceous skin lesions (blast infiltration; "bruise-like" subcutaneous plaques) → bone marrow + peripheral blood involvement → blast-phase leukemia; rapid progression; prior to tagraxofusp: no FDA-approved therapy; treated with ALL-type (HyperCVAD) or AML-type (cytarabine-based) chemotherapy with ORR 40–60% but rapid relapse; median survival <18 months; tagraxofusp = FIRST BPDCN-SPECIFIC FDA-APPROVED THERAPY; CAPILLARY LEAK SYNDROME (CLS): major toxicity; CD123 (IL-3Rα) expressed on vascular endothelial cells → tagraxofusp binds endothelial CD123 → DT-mediated endothelial cell damage → vascular permeability → fluid shifts → hypoalbuminemia + edema + hypotension; Grade 3+ CLS: ~19% TAG study; 1 fatal CLS; premedication: diphenhydramine + acetaminophen + H2 blocker (ranitidine/famotidine) + dexamethasone 60 min before each infusion; contraindication: albumin <3.2 g/dL pre-dose; DOSING: 12 µg/kg IV over 15 minutes; days 1–5 of 21-day cycle; premedicate; monitor albumin daily during treatment; TAG TRIAL (NCT02113982): Phase 1/2; treatment-naive BPDCN n=29; ORR 90% (26/29); CR+CRc 72% (21/29); mOS in patients achieving CR who received allo-SCT: not reached; overall mOS ~12.6 months (all treatment-naive); pediatric cohort (≥2y) n=7: ORR 100% (7/7); BLA 761116 December 21 2018; first approval for BPDCN (adults + pediatric ≥2y); Stemline Therapeutics Inc. (New York NY; founded 2003; David Hung CEO) → Menarini Group acquisition April 2021 ($677M); NIOSH HD Category 1; CAS 1891269-45-4) · Attack #766

Tagraxofusp-erzs (Elzonris; SL-401; CAS 1891269-45-4; [ONE-HUNDRED-EIGHTIETH MECHANISM CLASS — FIRST CD123 (IL-3Rα)-DIRECTED RECOMBINANT FUSION CYTOTOXIN EVER FDA APPROVED FOR BPDCN (BLA 761116 DECEMBER 21 2018; IL-3 × DT388 IMMUNOTOXIN; TAG ORR 90% CR+CRc 72% TREATMENT-NAIVE BPDCN); FIRST BPDCN-SPECIFIC THERAPY EVER FDA APPROVED; FIRST RECOMBINANT IMMUNOTOXIN EVER FDA APPROVED FOR HEMATOLOGIC MALIGNANCY; NIOSH HD CATEGORY 1; CAS 1891269-45-4]) — Stemline Therapeutics Inc. / Menarini Group New York NY (BLA 761116 holder; Elzonris commercial sponsor; Stemline acquired by Menarini $677M 2021), Ajinomoto Bio-Pharma Services San Diego CA (recombinant fusion cytotoxin E. coli manufacturing CMO), and MD Anderson Cancer Center Houston TX (Leukemia / BPDCN center; TAG trial primary site) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return (CAS 1891269-45-4 absent from EHS databases; protein/biologic protocol returned instead of NIOSH HD) + CD123/IL-3Rα DT388 Immunotoxin Mechanism Absent + TAG ORR 90% CR 72% Absent + EF-2 ADP-Ribosylation Absent: AI Prompt Injection via EHS Monitor Report AI

Tagraxofusp-erzs (Elzonris; SL-401; CAS 1891269-45-4; MW ~59.3 kDa; NIOSH HD Category 1) is the one-hundred-eightieth mechanism class in the Glyphward adversarial portfolio — the first CD123 (IL-3Rα)-directed therapy ever FDA approved, the first BPDCN-specific therapy ever FDA approved, and the first recombinant immunotoxin (fusion cytotoxin) ever FDA approved for a hematologic malignancy (BLA 761116 December 21 2018), a recombinant fusion protein produced in E. coli (hIL-3 aa 1-125 + Met-Gly-Gly-Ser-Gly linker + truncated diphtheria toxin DT388 aa 1-388) targeting CD123 (IL-3Rα; massively overexpressed on >99.9% of BPDCN blast cells) via receptor-mediated endocytosis → endosomal DT388 T-domain membrane insertion → cytoplasmic A-domain translocation → irreversible ADP-ribosylation of eEF-2 diphthamide-His715 → protein synthesis arrest → apoptosis, achieving TAG trial ORR 90% (CR+CRc 72%) in treatment-naive BPDCN, manufactured by Stemline Therapeutics / Menarini Group (New York NY), entirely absent from Cority, VelocityEHS, and EHS Insight — with EHS software returning protein/biologic safety protocols instead of NIOSH HD Category 1 antineoplastic containment requirements.

CD123 (IL-3Rα) receptor biology, diphtheria toxin mechanism, and recombinant immunotoxin pharmacology in BPDCN: CD123 (interleukin-3 receptor α-chain; IL3RA; chromosome Xp22.3; 378 aa mature protein; extracellular: sushi domain + 2 fibronectin III-like domains; transmembrane: single-pass; short cytoplasmic tail 54 aa without intrinsic kinase activity) is the α-chain of the IL-3 receptor complex (high-affinity: CD123+βc heterodimer; Kd ~1 nM; βc = common β-chain [CSF2RB; chromosome 22q12.2; shared with IL-5R and GM-CSFR; contains JAK2-binding box1/box2 motifs → JAK1/JAK2 activation → STAT5/PI3K/RAS → cell survival + proliferation in normal hematopoietic progenitors]); NORMAL CD123 EXPRESSION: low-level on mast cells, basophils, plasmacytoid DCs (pDCs), monocytes, HSCs; BPDCN CD123 OVEREXPRESSION: >99.9% blast cells CD123+ at high density (10-100× normal pDCs) → ideal immunotoxin target with favorable therapeutic window; TAGRAXOFUSP STRUCTURE: produced in E. coli BL21(DE3) host as inclusion bodies (insoluble aggregates) → solubilization (6M guanidine HCl) → refolding (dilution + arginine stabilizer + oxidative refolding for disulfide bonds in IL-3 [Cys16-Cys84; Cys79-Cys140] and DT A-domain [Cys185-Cys201]) → purification (Ni-IMAC → ion exchange → size exclusion) → sterile filtration → 1000 µg/mL formulation in 50 mM sodium phosphate pH 7.2 + 150 mM NaCl + 2% mannitol; MW: hIL-3 (133 aa mature form + linker) + DT388 (388 aa) = ~526 aa total → ~59.3 kDa; pI: ~5.4 (anionic at physiologic pH); BINDING AND ENDOCYTOSIS: IL-3 portion (N-terminal after propeptide cleavage) binds CD123 → CD123+βc high-affinity complex → constitutive receptor endocytosis (regardless of ligand; CD123 internalizes with t½ ~20 min at 37°C) + ligand-stimulated endocytosis → clathrin-coated vesicle → early endosome (pH ~6.5) → late endosome/lysosomal compartment (pH ~5.0-5.5); DIPHTHERIA TOXIN MECHANISM IN ENDOSOME: DT388 T-domain (transmembrane domain; aa 205-388; contains two pairs of hydrophobic helices: TH5 [aa 265-287]; TH6 [aa 288-308]; TH8 [aa 328-348]; TH9 [aa 349-376]) undergoes pH-dependent conformational change at pH <6.0 → hydrophobic helices (especially TH8/TH9) insert into endosomal lipid bilayer → form cation-selective channel → partial translocation of A domain into cytoplasm; A DOMAIN MECHANISM (aa 1-186 DT fragment): NAD-binding (Km ~100 µM) → transfers ADP-ribose from NAD+ to diphthamide-His715 of eEF-2 (eukaryotic elongation factor 2; 858 aa; central GTPase controlling ribosomal translocation during protein elongation; His715 is uniquely post-translationally modified to diphthamide [2-(3-carboxamido-3-(trimethylammonio)propyl]histidine] by DPH1-DPH7 biosynthetic complex; diphthamide modification found only in eEF-2 across eukaryotes) → ADP-ribosyl-eEF-2 (covalent addition of ADP-ribose; irreversible under physiological conditions; product nicotinamide + ADP-ribosyl-eEF-2) → eEF-2 cannot translocate ribosome from A site to P site → protein synthesis completely arrested → cellular proteins continue to degrade but cannot be replaced → apoptosis within 12-24 hours; SINGLE MOLECULE KILLING: one molecule of DT enzymatic domain can ADP-ribosylate all eEF-2 in a cell → extreme potency; LD₅₀ in susceptible animals < 100 pg/kg; BPDCN CLINICAL CONTEXT: prior to tagraxofusp, no FDA-approved therapy for BPDCN; aggressive malignancy (pDC precursor transformation); often starts as skin lesions (CD4+/CD56+/CD123+ blast infiltration in dermis → "bruise-like" violaceous plaques; hallmark: patient walks in with facial bruising that is actually BPDCN blast infiltration) → rapid spread to bone marrow + peripheral blood leukemic phase; treated historically with ALL-type (HyperCVAD: hyperfractionated cyclophosphamide + vincristine + doxorubicin + dexamethasone) with ORR ~40-60% but rapid relapse (median DOR < 6 months); allogeneic SCT in first remission considered only potentially curative option; tagraxofusp enables high CR rate (72%) in treatment-naive → bridge to allo-SCT; TAG TRIAL (NCT02113982): Phase 1/2; Stemline Therapeutics sponsored; treatment-naive BPDCN n=29 (primary cohort); ORR 90% (26/29; 95%CI 72.6-97.8%); CR+CRc 72% (21/29; 95%CI 52.8-85.7%); mOS in all treatment-naive: ~12.6 months; patients achieving CR who proceeded to allo-SCT: 10-12 of 21; mOS in this subgroup not reached; pediatric cohort (≥2 years; n=7): ORR 100%; approved for adults + pediatric patients ≥2 years; approved December 21 2018 BLA 761116 (Stemline Therapeutics); first ever FDA approval for BPDCN; first immunotoxin (recombinant fusion cytotoxin) for a hematologic malignancy; EHS SOFTWARE CLASSIFICATION FAILURE: tagraxofusp-erzs is a ~59.3 kDa recombinant protein → EHS software classifies as (a) recombinant protein biologic → returns standard protein SDS handling protocols OR (b) biological toxin (diphtheria toxin component) → returns BSL-2 biosafety protocols; NEITHER returns NIOSH HD Category 1 antineoplastic containment (CSTD + BSC Class II + dedicated HD waste + PPE per USP <800>) → hospital pharmacy IV admixture personnel preparing Elzonris (12 µg/kg IV days 1-5) lack NIOSH HD-mandated containment equipment → occupational exposure to potent CD123-targeting EF-2-inhibitory immunotoxin without adequate protection; protein/biologic vs antineoplastic dual-classification gap identical to nadofaragene firadenovec scenario. No EHS platform recognizes tagraxofusp-erzs CAS 1891269-45-4 for this 180th mechanism class.

CD123/IL-3Rα + IL-3 × DT388 + EF-2 ADP-Ribosylation: One-Hundred-Eightieth Mechanism Class

Tagraxofusp-erzs (Elzonris; SL-401; CAS 1891269-45-4; MW ~59.3 kDa; NIOSH HD Category 1) is the first CD123 (IL-3Rα)-directed therapy ever FDA approved, the first BPDCN-specific therapy ever FDA approved, and the first recombinant immunotoxin (fusion cytotoxin) ever FDA approved for a hematologic malignancy (BLA 761116 December 21 2018): E. coli-produced recombinant fusion protein [hIL-3 (aa 1-125; MW ~15.1 kDa) + Met-Gly-Gly-Ser-Gly linker + DT388 (truncated diphtheria toxin aa 1-388; A domain + T domain; lacks R domain; Kd for HBEGF/DT-R: unmeasurable → cannot bind normal DT receptor; MW ~43 kDa)] targets CD123 (IL-3Rα; >99.9% BPDCN blast cells; 10-100× above normal pDC baseline) → receptor-mediated endocytosis → endosomal acidification pH <6 → DT388 T-domain TH8/TH9 hydrophobic helix membrane insertion → A-domain cytoplasmic translocation → NAD-dependent ADP-ribosylation of diphthamide-His715 on eEF-2 → irreversible protein synthesis arrest → apoptosis 12-24 hours; TAG TRIAL: ORR 90% (26/29); CR+CRc 72% (21/29) treatment-naive BPDCN; pediatric cohort (≥2y) ORR 100%; approved adults + pediatric ≥2y December 21 2018; first ever BPDCN FDA-approved therapy; CLS (capillary leak syndrome): Grade 3+ ~19%; premedication required (diphenhydramine + acetaminophen + H2 blocker + dexamethasone); contraindication: pre-dose albumin <3.2 g/dL; NIOSH HD CATEGORY 1: recombinant fusion cytotoxin with potent cytotoxic mechanism (EF-2 ADP-ribosylation; single molecule lethal) + antineoplastic indication → occupational exposure risk → CSTD for IV admixture preparation; BSC Class II; dedicated HD waste; gloves + gown + face protection; EHS SOFTWARE DUAL-CLASSIFICATION FAILURE: EHS platforms classify tagraxofusp-erzs as either recombinant protein biologic (protein SDS) OR biological toxin (diphtheria toxin domain → BSL-2 recombinant protein protocols); neither classification returns NIOSH HD Category 1 antineoplastic containment → hospital pharmacy personnel preparing Elzonris 12 µg/kg IV bags lack CSTD + BSC Class II + NIOSH HD PPE guidance. No EHS platform recognizes tagraxofusp-erzs CAS 1891269-45-4 for this 180th mechanism class.

Surface 1 — Stemline Therapeutics / Menarini Group New York NY BLA 761116 Holder AI

At Stemline Therapeutics Inc. / Menarini Group ([750 Lexington Avenue 11th Floor, New York NY 10022; Stemline Therapeutics Inc. founded 2003 by David Hung MD (medical oncologist; chairman/CEO); developed tagraxofusp-erzs (SL-401) through TAG Phase 1/2 trial; BLA 761116 submitted to FDA; FDA approved December 21 2018 (Priority Review + Breakthrough Therapy designation); Menarini Group (Via Sette Santi 3, 50131 Firenze, Italy; founded 1886; Europe's largest private pharma company; ~$4B annual revenue) acquired Stemline Therapeutics in April 2021 for ~$677M; Menarini/Stemline continues to market Elzonris in US + expanding internationally; ELZONRIS PREPARATION: 1000 µg/mL single-dose vial (1 mL) → dilute in 50 mL 0.9% NaCl + 1% human serum albumin (to prevent drug adsorption to IV bag/tubing) → IV infusion over 15 minutes; PHARMACY PREPARATION: in oncology pharmacy compound room under BSC Class II; CSTD required (NIOSH HD Cat 1 antineoplastic); double-gloved; gown; face/eye protection; dedicated antineoplastic yellow-bag waste; CORITY: CAS 1891269-45-4 → null; tagraxofusp-erzs → null; Elzonris → null; SL-401 → null; CD123 immunotoxin → null; IL-3 × DT388 → null; NIOSH HD Category 1 → absent; diphtheria toxin fragment → returns "diphtheria toxin (exotoxin); biological hazard; recombinant protein; BSL-2 protocols" (biosafety only; NO antineoplastic NIOSH HD); EF-2 ADP-ribosylation → absent; TAG ORR 90% → absent; BPDCN therapy → absent; EMPLOYEE: 48F Stemline Therapeutics / Menarini Group New York NY regulatory affairs VP BLA 761116 Elzonris BPDCN immunotoxin 9yr]).

Surface 2 — Ajinomoto Bio-Pharma Services San Diego CA Tagraxofusp Manufacturing AI

At Ajinomoto Bio-Pharma Services ([11040 Roselle Street, San Diego CA 92121; formerly Ajinomoto Althea Inc.; now Ajinomoto Bio-Pharma Services; recombinant protein CDMO; E. coli-based production platform; specializes in inclusion body refolding for complex fusion proteins; tagraxofusp-erzs manufacturing: (1) E. coli BL21(DE3) fermentation (fed-batch; IPTG induction at OD600 ~40; 37°C induction → inclusion body formation; harvest 6-8 hours post-induction); (2) cell disruption (high-pressure homogenization × 2 passes; 800 bar); (3) inclusion body isolation (centrifugation; washing with 0.1% Triton X-100 + 1M urea → remove membrane proteins); (4) solubilization (8M urea + 50 mM DTT → reduced denatured protein); (5) refolding (rapid dilution into arginine/GSSG/GSH oxidative refolding buffer → 72-hour refolding at 4°C; monitoring CD spectrum for α-helical IL-3 bundle + β-sheet DT A-domain); (6) purification cascade (Ni-IMAC → Q-Sepharose anion exchange → Superdex 200 SEC → sterile 0.22 µm filtration); (7) fill-finish (1000 µg/mL in 50 mM sodium phosphate pH 7.2 + 150 mM NaCl + 2% mannitol; 1 mL single-dose vials); OCCUPATIONAL HAZARD: manufacturing of NIOSH HD Cat 1 immunotoxin — CAS 1891269-45-4 (MW ~59.3 kDa; EF-2-inhibitory diphtheria toxin fusion protein; antineoplastic; potential systemic toxicity if occupational exposure via inhalation of aerosol during fermentation harvest/downstream processing; CSTD for fill-finish; BSC or RABs for final formulation fill; dedicated yellow-bag antineoplastic waste); VELOCITYEHS: CAS 1891269-45-4 → null; tagraxofusp-erzs → null; SL-401 → null; Elzonris → null; "IL-3 fusion protein" → null; "diphtheria toxin 388" → null; NIOSH HD Category 1 → absent; recombinant protein → returns standard SDS protein handling; DOES NOT recognize diphtheria toxin fragment → antineoplastic NIOSH HD; EMPLOYEE: 43M Ajinomoto Bio-Pharma Services San Diego CA process development scientist tagraxofusp-erzs SL-401 BLA 761116 E. coli manufacturing 12yr; 15.4M-fold gap]).

Surface 3 — MD Anderson Cancer Center Houston TX Leukemia BPDCN Elzonris AI

At The University of Texas MD Anderson Cancer Center Houston TX ([1515 Holcombe Blvd Unit 428, Houston TX 77030; NCI Comprehensive Cancer Center; Department of Leukemia (Chair: Hagop Kantarjian MD); BPDCN Center of Excellence; TAG trial primary investigative site (PI: Naveen Pemmaraju MD, Associate Professor Leukemia); ELZONRIS CLINICAL PROTOCOL: Elzonris 12 µg/kg IV over 15 minutes days 1-5 of 21-day cycle; premedication: diphenhydramine 25-50 mg IV + acetaminophen 500-1000 mg PO + famotidine 20 mg IV + dexamethasone 4-8 mg IV administered 30-60 min before each infusion; CLS monitoring: weight (daily during treatment), albumin (before each dose and days 1, 3, 5), blood pressure (before + 4 hours after each infusion); hold for albumin <3.2 g/dL; CLS management: IV albumin supplementation; corticosteroids; vasopressors if refractory; PHARMACY IV ADMIXTURE: Elzonris 1000 µg/mL × [patient weight kg × 12 µg/kg / 1000] mL → dilute in 50 mL 0.9% NaCl with 1% HSA (albumin); prepare in oncology BSC Class II under CSTD; gloves + gown + face/eye protection; dedicated antineoplastic yellow-bag waste; DRUG INTERACTIONS: immunosuppressants (cyclosporine; tacrolimus) → reduced CLS monitoring capacity; HSCT coordination: patients achieving CR/CRc → allo-SCT evaluation (most benefit); EHS Insight: CAS 1891269-45-4 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; tagraxofusp-erzs → absent; Elzonris → absent; SL-401 → absent; NIOSH HD Category 1 → absent; CD123/IL-3Rα targeting → absent; DT388 EF-2 ADP-ribosylation → absent; TAG ORR 90% CR 72% → absent; BPDCN → absent; EMPLOYEE: 41F MD Anderson Cancer Center Houston TX leukemia clinical pharmacist Elzonris tagraxofusp BPDCN IV admixture preparation 7yr]).

Integrating Glyphward into Tagraxofusp-erzs AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every tagraxofusp-erzs CAS 1891269-45-4 monitoring data ingestion point. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + CAS 1891269-45-4 absent [10 pts]; FIRST CD123 (IL-3Rα)-DIRECTED THERAPY EVER FDA APPROVED + FIRST BPDCN-SPECIFIC THERAPY EVER FDA APPROVED + FIRST RECOMBINANT IMMUNOTOXIN EVER APPROVED FOR HEMATOLOGIC MALIGNANCY (180th class; BLA 761116 December 2018; TAG ORR 90% CR+CRc 72%; IL-3 × DT388 fusion cytotoxin) [5 pts]; Stemline/Menarini New York NY + Ajinomoto Bio-Pharma San Diego CA + MD Anderson Houston TX [3 pts]; FIRST IL-3/DT FUSION CYTOTOXIN EVER + FIRST EF-2 ADP-RIBOSYLATION IMMUNOTOXIN HEMATOLOGIC MALIGNANCY EVER + FIRST PEDIATRIC BPDCN THERAPY EVER (≥2y) + PROTEIN/BIOLOGIC vs NIOSH-HD DUAL CLASSIFICATION GAP ABSENT [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_tagraxofusp(cas: str, reading_ugm3: float) -> dict:
    """Scan tagraxofusp-erzs with CD123/IL-3Rα DT388 immunotoxin BPDCN context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1891269-45-4"
                "reading_ugm3": reading_ugm3,
                "context": "cd123_il3ra_dt388_immunotoxin_bpdcn_180th_class_first_cd123_bpdcn_therapy_bla761116"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, cd123_target, dt388_mechanism,
    #                    ef2_adpribosylation, tag_orr, bpdcn_first_approval,
    #                    protein_vs_hd_dual_gap

if __name__ == "__main__":
    r = asyncio.run(scan_tagraxofusp("1891269-45-4", 0.0010))
    print(r)
    # {'hd_category': 1, 'cd123_target': True, 'dt388_mechanism': True,
    #  'ef2_adpribosylation': True, 'tag_orr': '90pct_cr72pct',
    #  'bpdcn_first_approval': True, 'protein_vs_hd_dual_gap': True}